Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Dolutegravir (DTG) became central to South Africa's (SA's) first-line human immunodeficiency virus (HIV) regimen since 2019, offering improved tolerability, fewer drug-drug interactions, and a higher resistance barrier compared to efavirenz (EFV). Concerns remain about the long-term cardiovascular, metabolic, and renal consequences of DTG-based therapy in people living with HIV (PLHIV). This study compared demographic and clinical outcomes across three groups: (1) those on tenofovir, emtricitabine and efavirenz (TEE); (2) those on tenofovir, lamivudine and dolutegravir (TLD); and (3) those switched from TEE to TLD. METHODS: This retrospective, analytical study was conducted at an urban district hospital in KwaZulu-Natal. A sample of 212 patients was calculated using a chi-squared test for multiple proportions (80% power, 95% confidence interval). Data extracted at baseline, 6 and 12 months, were analysed with SPSS version 28.0. RESULTS: There were statistically significant differences between the three groups. The Switch group showed a higher incidence of new hypertension (HT) (9.9%, p = 0.03) and chronic kidney disease (CKD) (12.1%, p = 0.01). TLD group maintained stable outcomes. TEE group had the highest incidence of newly diagnosed dyslipidaemia. CONCLUSION: DTG-based therapy remains the preferred regimen in SA, its long-term metabolic and renal impact in patients switching from EFV warrants careful surveillance. The increased rates of HT and CKD in the Switch Group emphasises the need for closer monitoring to mitigate against complications.Contribution: This research contributes to the body of evidence on DTG, highlighting its benefits and the clinical challenges of managing ageing PLHIV with multimorbidity.
Source: South African Family Practice
Authors: Shira Kimberley, Mergan Naidoo
Institution: University of KwaZulu-Natal
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $856
OpenAlex ID: W4416064929